Loading
FGFR4 (Fibroblast growth factor receptor 4) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Sarcomas, Biliary tract cancer, Colorectal cancer and 5 more.
Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2.
CIViC holds 12 clinical evidence items and 0 assertions across 6 variants, naming FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074, Erlotinib, Sorafenib and Ponatinib and others. Open Targets scores its association with cancer at 0.84 (direct and indirect evidence; datatypes clinical 0.98, affected pathway 0.90, literature 0.99, genetic association 0.00, somatic mutation 0.87). IntOGen calls it a driver in 3 cohorts (0 activating, 3 loss-of-function), covering Glioblastoma Multiforme, Endometrial Carcinoma.
In plain words · FGFR4 (Fibroblast growth factor receptor 4) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Sarcomas, Biliary tract cancer, Colorectal cancer and 5 more.
FGFR4 (Fibroblast growth factor receptor 4) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Sarcomas, Biliary tract cancer, Colorectal cancer and 5 more.
Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis.
No product in this corpus aims at FGFR4 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA FGFR4: RNA tissue enhanced (liver 82 nTPM, lung 63 nTPM); no normal tissue stained high. Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Sarcomas (soft tissue, bone, GIST), Biliary tract cancer (all types), Colorectal cancer, Lung cancer (all types), Breast cancer (all types), Gastric & gastro-oesophageal junction cancer, Ovarian cancer and more); Open Targets associates it with 5 specific cancer types at or above 0.5 (urothelial carcinoma, rhabdomyosarcoma, cholangiocarcinoma, non-small cell lung carcinoma, breast carcinoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P22455; CIViC gene FGFR4; IntOGen FGFR4; Human Protein Atlas FGFR4 tissue; Open Targets ENSG00000160867 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Partanen et al, Proc. Natl. Acad. Sci. U.S.A, 1990, "Putative tyrosine kinases expressed in K-562 human leukemia cells". Source.
Sources: HGNC HGNC:3691 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P22455 (protein name, function text, keywords and locations (REST API)); CIViC gene FGFR4 (12 evidence items, 0 assertions, 6 variants; diseases: Lung Adenocarcinoma, Rhabdomyosarcoma, Ovarian Cancer, Stomach Cancer, Ewing Sarcoma and 4 more (GraphQL API, CC0)); Open Targets ENSG00000160867 (association with cancer (MONDO_0004992) 0.84; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.61, colorectal cancer 0.64, gastric cancer 0.51, cholangiocarcinoma 0.59, urinary bladder cancer 0.57, melanoma 0.60 (GraphQL API, CC0)); IntOGen FGFR4 (driver in 3 cohorts (Act 0, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signalling cascades. Activation of PLCG1 leads to the production of the cellular signalling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signalling pathway, as well as of the AKT1 signalling pathway. Location: Cell membrane; Endosome; Endoplasmic reticulum; Secreted (UniProt). Locus 5q35.2 (HGNC).
RNA: tissue enhanced (liver 82 nTPM, lung 63 nTPM), detected in many normal tissues.
No normal tissue stained high; medium in Adrenal gland, Appendix, Colon, Duodenum, Gallbladder, Kidney and more.
No cancer stained high; medium in breast cancer, colorectal cancer, liver cancer, lung cancer.
HPA FGFR4 tissue · HPA FGFR4 pathology · HPA protein class: CD markers, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FGFR4" OR ABSTRACT:"FGFR4" OR TITLE:"fibroblast growth factor receptor 4" OR ABSTRACT:"fibroblast growth factor receptor 4" OR TITLE:"Fibroblast growth factor receptor 4" OR ABSTRACT:"Fibroblast growth factor receptor 4" OR TITLE:"JTK2" OR ABSTRACT:"JTK2" OR TITLE:"CD334" OR ABSTRACT:"CD334") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FGFR4, not a curated reading list.
Shares Biliary tract cancer (all types), Hepatocellular carcinoma, CIViC, IntOGen.
Shares Biliary tract cancer (all types), Hepatocellular carcinoma, IntOGen, Gastric & gastro-oesophageal junction cancer.
Shares Biliary tract cancer (all types), CIViC, IntOGen, Gastric & gastro-oesophageal junction cancer.
Shares Biliary tract cancer (all types), Hepatocellular carcinoma, CIViC, IntOGen.
Shares Biliary tract cancer (all types), IntOGen, Lung cancer (all types), Breast cancer (all types).
Shares Biliary tract cancer (all types), Hepatocellular carcinoma, CIViC, IntOGen.
Shares Biliary tract cancer (all types), CIViC, IntOGen, Gastric & gastro-oesophageal junction cancer.
Shares Biliary tract cancer (all types), IntOGen, Lung cancer (all types), Open Targets Platform.